key: cord-0785452-bv5w6db6
authors: Artusi, Carlo Alberto; Romagnolo, Alberto; Imbalzano, Gabriele; Marchet, Alberto; Zibetti, Maurizio; Rizzone, Mario Giorgio; Lopiano, Leonardo
title: COVID-19 in Parkinson's disease: Report on prevalence and outcome
date: 2020-09-06
journal: Parkinsonism Relat Disord
DOI: 10.1016/j.parkreldis.2020.09.008
sha: bc6c6b72a87c4e05947acf8de7e42009309cf063
doc_id: 785452
cord_uid: bv5w6db6

nan

confirmed cases worldwide. COVID-19 has had a relevant impact in the field of Neurology, challenging the management of patients with chronic neurologic conditions who have, or are at risk for, the infection [1, 2] . Parkinson's disease (PD), affecting 1-2 per 1,000 of the population at any time, and 1% of the population above 60 years, is the second most common neurodegenerative disease, with over 250,000 patients in Italy, and over 1,000,000 in USA. The potential neurotropism of COVID-19 and the finding of antibodies against coronavirus in the cerebrospinal fluid of PD patients prompted questions about the susceptibility of PD patients to COVID-19 [2] [3] [4] [5] [6] . To date, only two case series for a total of 12 PD patients and one community-based study were published about PD and COVID-19 [3, 4, 6] , suggesting worsening of motor and non-motor symptoms and an association between higher mortality rates (40%) and older age and longer PD duration [3, 4] . Also, a recent large case-control study performed on a single-center in Lombardy, Italy, reported an interview to non-advanced PD patients [5] . The authors found a similar rate of infection in PD patients and controls and suggest that COVID-19 risk and mortality did not differ from the general population. However, the prevalence of PD patients affected by COVID-19 is still unknown [1] .

Here, we aimed to estimate the prevalence of COVID-19 in a large population of PD patients and compare the infection rate with the general population of the same region. To this end, we Table 1 . PD symptoms worsened in all patients, early before or early after the onset of infection signs, which consisted in fever (100% of patients), weakness (43%), muscle pain (29%), dyspnea (29%), and cough (14%). Interestingly, one patient developed disabling dyskinesia as the presenting symptom of the infection. All patients were hospitalized, and three were already institutionalized at the moment of infection. All were treated with levodopa, alone or in combination with dopamine agonists. One patient was treated with levodopa/carbidopa intestinal gel infusion plus entacapone. PD therapy was modified in two cases: in one case, the dosage of levodopa was increased, while in the other dopaminergic therapy was stopped as the patient's conditions worsened.

To our knowledge, this is the first report of the prevalence of confirmed COVID-19 cases in a large cohort of PD patients living in a specific geographic area. Notably, the prevalence was equivalent to J o u r n a l P r e -p r o o f 5 that of the general population. Whether a similar prevalence is related to the same predisposition for COVID-19 infection or to a higher level of attention and self-isolation in PD patients (as an at-risk population) cannot be elucidated by our data. However, differently from a previous similar study, we found a high rate of mortality among PD patients [5] . This discrepancy might be due to the fact that the study of Lombardy patients did not consider advanced PD patients and those living in nursing homes or other long-term care facilities. On the other hand, another study considering the outcome of PD patients affected by COVID-19 found a 'substantially high mortality rate (40%)', suggesting that older age and longer disease duration might be predictors of worse outcomes [3] .

Limitations intrinsic to this kind of study notwithstanding, our data might cautiously suggest that PD patients should not be necessarily considered at higher risk for developing COVID-19, but might be at higher risk for a worse outcome, especially if they have a long PD duration. Further studies on larger cohorts of PD patients affected by COVID-19 are needed to confirm this finding.

J o u r n a l P r e -p r o o f AKNOWLEDGMENT The Authors would like to express their gratitude to the personnel and all the members of the "Associazione Amici Parkinsoniani Piemonte", which collaborated with the regional section of the Italian Association of Parkinsonian patients "Gianni Cavallari", and in particular to their president, U. Pilotto.

Location Contribution J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

MDS-cientific Issues Committee, Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Outcome of Parkinson's Disease Patients Affected by COVID-19

Effects of COVID-19 on Parkinson's disease clinical features: a communitybased case-control study

COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy

Rapid worsening in Parkinson's disease may hide COVID-19 infection